Omalizumab (OMZ) is a humanized monoclonal antibody that binds free IgE, thereby blocking subsequent interaction with its receptors, and is approved for treatment of severe asthma and chronic urticaria in both the US and Europe (88, 89). Here, IGHE is linked to asthma.